Background: Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period.Methods: The survey comprised 12 questions regarding the availability of SP142 in the pathology departments, the percentage of positive tests, the difficulties of pathologists in cases close to cut-off value and the tested samples.Results: The SP142 assay was available in only eight centers. In case of positive result, most centers (5/8, 62.5%) reported values of PD-L1 expression ranging from > 1 to <= 5%, with values close to the cut-off point (>= 1% or < 1%) being the greatest challenge. Most of the centers (6/8, 75%) tested material from both their own and other hospitals. In most centers, the evaluations were performed either on primary tumors or metastasis, in particular lymph nodes (5/8, 62.5%), followed by lung (3/8, 37.5%) and liver (1/8, 12.5%) metastasis.Conclusion: Our results raise some important issues concerning the evaluation of PD-L1 in the "real-life" setting, providing strategies for its implementation.
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey / Cerbelli, Bruna; Cirillo, Alessio; Pomati, Giulia; Pernazza, Angelina; Ascione, Andrea; Pisegna, Simona; Pisano, Annalinda; Leopizzi, Martina; Pignataro, Maria Gemma; Costarelli, Leopoldo; Mulè, Antonino; Vecchione, Andrea; Catalano, Piera; Coppola, Luigi; Perrone, Giuseppe; Perracchio, Letizia; Anemona, Lucia; Mastracchio, Antonio; Nardi, Stefano; Reitano, Renato; Massari, Annalisa; Grillo, Lucia Rosalba; Liberati, Fabrizio; Della Rocca, Carlo; Marchetti, Paolo; Botticelli, Andrea; D’Amati, Giulia. - In: TUMORI. - ISSN 0300-8916. - 110:1(2024), pp. 44-48. [10.1177/03008916231196781]
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey
Cerbelli, Bruna;Cirillo, Alessio;Pomati, Giulia;Pernazza, Angelina;Ascione, Andrea;Pisano, Annalinda;Leopizzi, Martina;Pignataro, Maria Gemma;Vecchione, Andrea;Catalano, Piera;Coppola, Luigi;Mastracchio, Antonio;Massari, Annalisa;Della Rocca, Carlo;Botticelli, Andrea
;
2024
Abstract
Background: Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period.Methods: The survey comprised 12 questions regarding the availability of SP142 in the pathology departments, the percentage of positive tests, the difficulties of pathologists in cases close to cut-off value and the tested samples.Results: The SP142 assay was available in only eight centers. In case of positive result, most centers (5/8, 62.5%) reported values of PD-L1 expression ranging from > 1 to <= 5%, with values close to the cut-off point (>= 1% or < 1%) being the greatest challenge. Most of the centers (6/8, 75%) tested material from both their own and other hospitals. In most centers, the evaluations were performed either on primary tumors or metastasis, in particular lymph nodes (5/8, 62.5%), followed by lung (3/8, 37.5%) and liver (1/8, 12.5%) metastasis.Conclusion: Our results raise some important issues concerning the evaluation of PD-L1 in the "real-life" setting, providing strategies for its implementation.File | Dimensione | Formato | |
---|---|---|---|
cerbelli-et-al-2023-pd-l1-testing-in-metastatic-triple-negative-breast-cancer-results-of-an-italian-survey.pdf
accesso aperto
Note: Cerbelli_PD-L1 testing_2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
136.66 kB
Formato
Adobe PDF
|
136.66 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.